Recruiting NA INTERVENTIONAL 1-arm NCT06740370

TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

TACE Combined With Lenvatinib and PD-1 Inhibitor for Spontaneous Rupture of Hepatocellular Carcinoma: a Prospective Multicenter Study

Sponsor: Sun Yat-sen University

Conditions Anti-PD1 Antibody Hepatocellular Carcinoma Lenvatinib Transcatheter Arterial Chemoembolization

Interventions Lenvatinib PD-1 Inhibitors TACE

Updated 2 times since 2025 Last updated: Aug 10, 2025 Started: Dec 13, 2024 Primary completion: Dec 30, 2025 Completion: Aug 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Anti-PD1 Antibody and Hepatocellular Carcinoma and is currently actively recruiting participants. Sun Yat-sen University leads this study, which shows 2 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

2 versions recorded

Sep 2025 — Present [monthly]

Recruiting NA
Jan 2025 — Sep 2025 [monthly]

Recruiting NA

First recorded

Dec 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China